ALGS
Aligos Therapeutics Inc

1,203
Mkt Cap
$69.72M
Volume
50,884.00
52W High
$46.80
52W Low
$3.76
PE Ratio
-0.58
ALGS Fundamentals
Price
$11.51
Prev Close
$11.33
Open
$11.30
50D MA
$9.11
Beta
1.82
Avg. Volume
82,553.26
EPS (Annual)
-$20.94
P/B
0.99
Rev/Employee
$56,357.14
Loading...
Loading...
News
all
press releases
Does Aligos Therapeutics (ALGS) Have the Potential to Rally 737.74% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 737.7% in Aligos Therapeutics (ALGS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·3mo ago
News Placeholder
More News
News Placeholder
Sanofi Gets FDA Nod for Wayrilz in Immune Thrombocytopenia
SNY wins FDA approval for Wayrilz, the first BTK inhibitor for immune thrombocytopenia, with broader rare disease studies underway.
Zacks·3mo ago
News Placeholder
RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study
Rocket Pharmaceuticals' shares soar as the FDA lifts its clinical hold on the pivotal Danon disease gene therapy study.
Zacks·4mo ago
News Placeholder
Wall Street Analysts Predict a 983.24% Upside in Aligos Therapeutics (ALGS): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 983.2% in Aligos Therapeutics (ALGS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·4mo ago
News Placeholder
Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus
ALLO posts a narrower second-quarter 2025 loss. The company advances multiple CAR T programs targeting cancer and autoimmune diseases.
Zacks·4mo ago
News Placeholder
Aligos Therapeutics, Inc. (ALGS) Reports Q2 Loss, Misses Revenue Estimates
Aligos Therapeutics (ALGS) delivered earnings and revenue surprises of +34.89% and -3.50%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago

Latest ALGS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.